Literature DB >> 17551766

Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur.

J Fox1, M A Miller, R R Recker, C H Turner, S Y Smith.   

Abstract

Treatment of monkeys and humans with parathyroid hormone (PTH) 1-84 stimulates skeletal remodeling, which increases trabecular (Tb) bone mineral density (BMD) but decreases cortical (Ct) BMD at locations where these bone types predominate. We report the effects of daily PTH treatment (5, 10, or 25 microg/kg) of ovariectomized (OVX) rhesus monkeys for 16 months on bone structure and biomechanical properties at the proximal femur, a mixed trabecular and cortical bone site. PTH reversed the OVX-induced decrease in BMD measured by dual-energy X-ray absorptiometry at the proximal femur, femoral neck, and distal femur. Peripheral quantitative computed tomography confirmed a significant decrease in Ct.BMD and an increase in Tb.BMD at the total proximal femur and at the proximal and distal femoral metaphyses. The decrease in Ct.BMD resulted primarily from increased area because cortical bone mineral content was unaffected by PTH. Histomorphometry revealed that PTH significantly increased the trabecular bone formation rate (BFR) as well as trabecular bone volume and number. PTH did not affect periosteal or haversian BFR at the femoral neck, but cortical porosity was increased slightly. PTH had no effects on stiffness or peak load measured using a shear test, whereas work-to-failure, the energy required to fracture, was increased significantly. Thus, PTH treatment induced changes in trabecular and cortical bone at the proximal femur that were similar to those occurring at sites where these bone types predominate. Together, the changes had no effect on stiffness or peak load but increased the energy required to break the proximal femur, thereby making it more resistant to fracture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551766     DOI: 10.1007/s00223-007-9036-y

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  4 in total

1.  Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.

Authors:  Sarah K Amugongo; Wei Yao; Junjing Jia; Weiwei Dai; Yu-An E Lay; Li Jiang; Danielle Harvey; Elizabeth A Zimmermann; Eric Schaible; Neil Dave; Robert O Ritchie; Donald B Kimmel; Nancy E Lane
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

2.  Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents.

Authors:  Mohammad Shahnazari; Wei Yao; Bob Wang; Brian Panganiban; Robert O Ritchie; Yolanda Hagar; Nancy E Lane
Journal:  J Bone Miner Res       Date:  2011-03       Impact factor: 6.741

3.  Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.

Authors:  N Doyle; A Varela; S Haile; R Guldberg; P J Kostenuik; M S Ominsky; S Y Smith; G Hattersley
Journal:  Osteoporos Int       Date:  2017-12-19       Impact factor: 4.507

4.  Is the Jaw Bone Micro-Structure Altered in Response to Osteoporosis and Bisphosphonate Treatment? A Micro-CT Analysis.

Authors:  Marissa Chatterjee; Fernanda Faot; Cassia Correa; Jente Kerckhofs; Katleen Vandamme
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.